SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.
http://mrem.bernama.com/viewsm.php?idm=41919
- Kenya to host ministerial meeting to advance school meals worldwide
- Omani, Iranian FMs Discussed Regional Developments, Israeli Attacks On Iran
- 2,672 Killed, 12,468 Injured In Israeli Airstrikes On Lebanon: Health Ministry
- Lebanese Minister Warns Against Interaction With Israeli Accounts On Social Media
- Sudan crisis: New wave of mass killings alarms UN
- Iran Smashed “Terrorists” Behind Deadly Attack On Security Forces
- Japan’s Ruling Coalition On Edge As LDP Falls Short Of Majority In General Election
- Uzbekistan Held First Mixed-System Parliamentary Election
- NPP Secures First Local Election Victory For Nov Parliamentary Vote In Sri Lanka
- Israeli Regime Completed Airstrike On Iranian Targets, Tehran Reported “Limited Damage”